Darolutamide: an androgen receptor inhibitor for the treatment of prostate cancer

doi:10.3969/j.issn.1672-3384.2026.08.003

PDF(559 KB)

Clinical Medication Journal ›› 2026, Vol. 24 ›› Issue (8) : 11-16. DOI: 10.3969/j.issn.1672-3384.2026.08.003

Comment of New Drug

Darolutamide: an androgen receptor inhibitor for the treatment of prostate cancer

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 24(8): 11-16 https://doi.org/10.3969/j.issn.1672-3384.2026.08.003

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(559 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2026-04-23	2026-08-25
Issue Date
2026-09-03

Please choose a citation manager

Content to export